“Experimental evidence suggests that endocannabanoids, molecules found in the body that closely resemble compounds found in the cannabis (marijuana) plant, may play a role in limiting intestinal inflammation. IBD patients have been found to have higher levels of cannabinoid receptors in their colonic tissue. Several small studies have shown that a significant proportion of patients with IBD report smoking marijuana to relieve IBD-related symptoms, particularly those patients with a history of abdominal surgery, chronic abdominal pain, and/or a low quality of life index. However, the medicinal use of marijuana is limited by potential side effects, the risk of smoking, and the lack of direct scientific evidence of clinical effectiveness for intestinal inflammation.

The CCFA does not endorse the smoking of marijuana by IBD patients, any current state-based medical marijuana programs, or the legalization of marijuana. The CCFA does support the calls by the various health organizations urging review of marijuana’s status as a federal Schedule I controlled substance, with the goal of facilitating the conduct of clinical research and the potential development of cannabanoid-based medications.”

Jan. 2012 – Crohn’s & Colitis Foundation of America (CCFA)

[Editor’s Note: Prior to CCFA’s Not Clearly Pro or Con position, the organization held a Con position as indicated in its Aug. 4, 2005 statement below:]

“CCFA’s medical leadership does not support the use of ‘medical marijuana’ in people with IBD [Inflammatory Bowel Disease].

While marijuana might temporarily reduce pain and nausea, there is, as yet, no evidence that it can control chronic intestinal inflammation–the underlying cause of these symptoms in Crohn’s disease or ulcerative colitis…

CCFA’s expert consensus remains: The harmful side effects of marijuana far outweigh its potential benefits.”

Aug. 4, 2005